All In Biotech

Drug Trial Radar · NCT01855750

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 838 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

838

Actual

Start

Sep 3, 2013

Primary completion

Feb 26, 2018

Study completion Apr 5, 2019

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Pharmacyclics LLC.
First posted
May 16, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the clinical outcome in newly diagnosed patients with non-germinal center B-cell subtype (GCB) of diffuse large B-cell lymphoma (DLBCL) selected by immunohistochemistry (IHC) or newly diagnosed patients with activated B cell-like (ABC) subtype of DLBCL identified by gene expression profiling (GEP) or both populations.

Conditions

  • Lymphoma

Interventions

  • IbrutinibDrug

    560 mg capsules administered by mouth once daily (21-day cycles)

  • PlaceboDrug

    4 matched capsules administered by mouth once daily (21-day cycles)

  • RituximabDrug

    375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

  • CyclophosphamideDrug

    750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

  • DoxorubicinDrug

    50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

  • VincristineDrug

    1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)

  • Prednisone (or equivalent)Drug

    100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-Free Survival (EFS) - Intent-to-Treat (ITT) PopulationTime frame: Up to 5.5 years
  2. Event-Free Survival (EFS) - Activated B-Cell (ABC) PopulationTime frame: Up to approximately 4.5 years

Locations

201 sites in 27 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    Greenbrae, California

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Salinas, California

  • Site not named

    Stanford, California

  • Site not named

    Danbury, Connecticut

  • Site not named

    Hartford, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Peoria, Illinois

  • Site not named

    Fort Wayne, Indiana

  • Site not named

    Goshen, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Topeka, Kansas

  • Site not named

    Louisville, Kentucky

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Bethesda, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Hackensack, New Jersey

  • Site not named

    New Brunswick, New Jersey

  • Site not named

    Fresh Meadows, New York

  • Site not named

    Johnson City, New York

  • Site not named

    Mineola, New York

  • Site not named

    New York, New York

  • Site not named

    Rochester, New York

  • Site not named

    The Bronx, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Greenville, North Carolina

  • Site not named

    Hickory, North Carolina

  • Site not named

    Columbus, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    North Charleston, South Carolina

  • Site not named

    Nashville, Tennessee

Showing 40 of 201 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.